Treatment for advanced lung cancer after targeted therapy and chemotherapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new treatment for advanced non-small cell lung cancer that has stopped responding to targeted therapy and chemotherapy. The goal is to find a treatment that works better for people whose cancer has certain genetic changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer must have a specific genetic change (in ALK, EGFR, HER2, MET, NTRK, RET, or ROS1) that has been treated with an approved targeted therapy.
- Your cancer must have grown or spread during or after your most recent treatment.
- You must have had chemotherapy that contains platinum, and you can have had no more than 3 prior chemotherapy-type treatments.
- You have not had immunotherapy (like PD-1 or PD-L1 inhibitors) or certain types of antibody-drug conjugates before.
- You must be well enough to carry out daily activities (performance status 0-1) and have adequate organ function.
- You must have measurable disease on a CT or MRI scan, and any brain metastases must be stable and not require immediate treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
This study looks at blood and tissue biomarkers to predict how well immunotherapy (with or without chemotherapy) works for advanced non-small cell lung cancer. It also helps decide the best second treatment if the first one stops working.
This trial tests a targeted therapy for people with advanced non-small cell lung cancer whose tumors have extra copies of the MET gene. It's for those whose cancer has progressed after at least one prior treatment.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial studies how well targeted therapy works for advanced non-small cell lung cancer (NSCLC) that has spread. You may qualify if you have a specific gene change and are starting your first targeted treatment.
Hear when a new Recurrent Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.